These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 33302841)
1. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. Godinez-Leiva E; Bril F Curr Hypertens Rev; 2021; 17(2):94-111. PubMed ID: 33302841 [TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Basu R; Noureddin M; Clark JM Mayo Clin Proc; 2022 Sep; 97(9):1700-1716. PubMed ID: 36058582 [TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Ota T Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745 [TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease from a primary care perspective. Clark JM; Cryer DRH; Morton M; Shubrook JH Diabetes Obes Metab; 2023 Jun; 25(6):1421-1433. PubMed ID: 36789676 [TBL] [Abstract][Full Text] [Related]
5. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease]. Zhu C; Zhou D; Fan J Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471 [TBL] [Abstract][Full Text] [Related]
6. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i. Pattison RJ; Esteban JP; Sempokuya T; Kewcharoen J; Kalathil S; Kuwada SK Hawaii J Health Soc Welf; 2020 Jun; 79(6):180-186. PubMed ID: 32524096 [TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Vieira Barbosa J; Lai M Hepatol Commun; 2021 Feb; 5(2):158-167. PubMed ID: 33553966 [TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Khneizer G; Rizvi S; Gawrieh S Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. Kuchay MS; Choudhary NS; Mishra SK; Misra A Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648 [TBL] [Abstract][Full Text] [Related]
11. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
13. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197 [No Abstract] [Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804 [TBL] [Abstract][Full Text] [Related]
15. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management]. Kim SK; Kim KI; Kim SR Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630 [TBL] [Abstract][Full Text] [Related]
16. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Lomonaco R; Chen J; Cusi K Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186 [TBL] [Abstract][Full Text] [Related]
17. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]